Payment overview · 2025
General Payments
$134.82
7 reported records · 6 companies
Healthcare provider profile · identity verified
Ashlee Dougherty, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MEXICO, MO · NPI 1801416599
Verified facts
What the public records show
CMS Open Payments records show Ashlee Dougherty, PA-C received $134.82 in general payments during 2025 across 7 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.40 | 23.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.10 | 23.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.88 | 16.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.97 | 14.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.08 | 12.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.39 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $134.82 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 55 |
| Lisinopril | Lisinopril | 228 | 61 |
| Meloxicam | Meloxicam | 206 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 40 |
| Omeprazole | Omeprazole | 159 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 35 |
| Prednisone | Prednisone | 134 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 29 |
| Losartan Potassium | Losartan Potassium | 107 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 37 |
| Metformin Hcl | Metformin Hcl | 97 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 22 |
| Furosemide | Furosemide | 86 | 20 |
| Gemfibrozil | Gemfibrozil | 84 | suppressed |
| Gabapentin | Gabapentin | 72 | 16 |
| Metformin Hcl Er | Metformin Hcl | 71 | 15 |
| Sertraline Hcl | Sertraline Hcl | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 61 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | suppressed |
| Simvastatin | Simvastatin | 60 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 48 |
| Potassium Chloride | Potassium Chloride | 59 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 13 |
| Atenolol | Atenolol | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Glimepiride | Glimepiride | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 14 |
| Glipizide | Glipizide | 54 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 36 |
| Baclofen | Baclofen | 39 | 15 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Azithromycin | Azithromycin | 28 | 28 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 27 | 26 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Estradiol | Estradiol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134.82 · 7 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, REXULTI, VOQUEZNA, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error